Latest Breaking News On - European hematology association - Page 3 : comparemela.com

Samsung Bioepis to Present Post-hoc Analysis of Phase 3

Post-hoc analysis of Phase 3 study to highlight transfusion avoidance results of SB12 compared to reference eculizumab-treated groups INCHEON, Korea, May .

Eculizumab biosimilarYounsoo kimSamsung bioepisJihyun hanPaola russoHyejin kimHus laboratory monitoringLifecycle safety team leader at samsung bioepisEuropean hematology associationLaboratory monitoringSamsung bioepis co ltdEuropean unionEuropean medicines agencyEuropean commissionAlexion pharmaceuticalsHybrid congress

Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)

Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United kingdomBecker hewesMastocytosis advEuropean hematology associationBlueprint medicines corporationEuropean academy of allergyPrnewswire blueprint medicines corporation nasdaqEuropean commissionPatient surveyExchange commissionDrug administrationPatient survey abstractMedicines corporationClinical immunologyHematology associationHybrid congress

Isatuximab Gets Priority Review for Transplant-Ineligible Multiple Myeloma

Isatuximab Gets Priority Review for Transplant-Ineligible Multiple Myeloma
empr.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from empr.com Daily Mail and Mail on Sunday newspapers.

United statesEuropean hematology associationAmerican society of clinical oncologyDrug administrationPriority reviewBiologics license applicationClinical oncologyAnnual meetingHematology association

Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma

Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

France generalUnited statesFelix lauscherCorentine driancourtDietmar bergerTimothy gilbertThomas larsenNicolas obristTarik elgoutniEvan berlandAmerican society of clinical oncologyDrug administrationWorld health organizationEuropean hematology associationGlobal head of development at sanofiEuropean union

Sarclisa Accepts for FDA Priority Review for the Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma

The U.S. Food and Drug Administration has accepted for Priority Review the supplemental Biologics License Application for the investigational use of Sarclisa in combination with bortezomib,.

United statesDrug administrationEuropean unionEuropean hematology associationAmerican society of clinical oncologyPriority reviewBiologics license applicationClinical oncologyAnnual meetingHematology associationNonproprietary namingBiological products guidance